Presenters
Overview
Update: This webinar has been rescheduled to Tuesday, November 10, 2020.
Assessment of Needs
Opioid use disorder is a growing crisis among people in the US, and people with HIV (PWH) are particularly affected. This talk will summarize the current knowledge in the field (eg, epidemiology, neurobiology) and will present a real-world, stepwise approach to opioid use disorder among PWH or hepatitis that can be implemented in any clinical setting. This talk will include both nonpharmacological interventions (eg, brief motivational interventions), as well as pharmacological interventions (eg, buprenorphine).
This webinar is part 3 of the 4-part webinar series on pain and addiction:
- Part 1: Chronic Pain in People With HIV: An Evidence-Based, Practical Approach by Dr Jessica Merlin, MD, PhD, MBA (University of Pittsburgh)
- Part 2: Medical Cannabis in People With HIV: What’s the Evidence by Dr Jessica Merlin, MD, PhD, MBA (University of Pittsburgh)
- Part 4: More Than One Problem: Mental Illness as a Contributing Factor of Pain and Substance Use in People With HIV by Dr R. Douglas Bruce, MD, MA, MS (Yale School of Medicine)
Learning Objectives
Upon completion of this webinar, learners will be able to:
- Describe the basic methods of screening for and addressing opioid use in people with HIV
- Explain how to initiate treatment for opioid use disorders
- Implement the basic principles of treating HIV and HCV in people with opioid use disorder
Registration
Note: The IAS–USA acknowledges the importance of delivering the same high-quality education and resources to our audiences despite the challenging times we are experiencing due to the COVID-19 pandemic. In response, the implementation of a nominal fee to process the claim of CME and CE credits for webinars has been postponed.
Who Should Attend
This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for registered nurses, PharmDs, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Monday, November 2, 2020, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”
Presenter
Dr Bruce has no relevant financial affiliations to disclose. (Updated 11/03/20)
Reviewer
Dr Andrew I. Aronsohn has no relevant financial affiliations to disclose. (Updated 11/03/20)
CME Planner and Reviewer
Ms Donna M. Jacobsen has no relevant financial affiliations to disclose. (Updated 11/03/20)
Continuing Education Credits
CME Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nursing Credits
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Pharmacy Credits
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-20-346-L02-P
This program is approved for 1.25 hours of pharmacotherapy credit.
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
PLATINUM SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare
SILVER SUPPORTER
Janssen Therapeutics
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.